Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2100512 | 0.89 | GPR119 (0.44) | GPR119MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL2100515 | 0.89 | GPR119 (0.44) | GPR119MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL2103090 | 0.80 | THRB (0.48) | GPR119MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL28812695 | 0.79 | GPR119 (0.54) | GPR119MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL2102582 | 0.77 | RBP4 (0.34) | — | |
| SCHEMBL2102580 | 0.77 | RBP4 (0.34) | — | |
| SCHEMBL3467159 | 0.76 | GPR119 (0.51) | GPR119MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL18739558 | 0.74 | MAPT (0.54) | GPR119MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL18739546 | 0.73 | MAPT (0.53) | GPR119MAPTSMN1; SMN2TP53THRB | |
| SCHEMBL17857192 | 0.73 | MAPT (0.53) | GPR119MAPTSMN1; SMN2TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163737-B2 | CGRP receptor antagonists | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176769-A1 | CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, GRPR | GPR119 142/4885MAPT 2525/4885SMN1; SMN2 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.